MK-677 (Ibutamoren) Side Effects

Reported MK-677 (Ibutamoren) side effects

MK-677 has the most pronounced side-effect profile of any GHS compound - specifically because its 24-hour half-life produces sustained rather than pulsatile receptor engagement. In the 2-year trial the most frequent effects were increased appetite (29 of 43 people on MK-677 against 8 of 22 on placebo), mild transient leg edema (19 of 43 against 6 of 22) and transient muscle pain (14 of 43 against 2 of 22) (Nass et al., 2008). Common (>20% of users) Appetite increase - the signature MK-677 effect; direct ghrelin-receptor agonism on hypothalamic feeding neurons. In the 2-year trial appetite rose in 29 of 43 people on MK-677 against 8 of 22 on placebo and returned to normal within 3 months in half of them; caloric intake was not measured. Primarily evening and nocturnal (because that's when the pre-bed dose peaks) Water retention / mild peripheral edema - fluid-shift from GH and IGF-1 elevation plus sustained ghrelin-receptor tone. Typically 1-3 kg of scale weight in the first 2 weeks; settles by week 4 in most users; peripheral edema should resolve by week 6-8 Lethargy / "heavy" feeling - particularly in the first 2-3 weeks; fluid-related; most users report this resolves but some stay lethargic through the cycle Vivid dreams / altered sleep - usually positive (deeper SWS) but can be disruptive in the first week Transient mild numbness / tingling in hands - water-retention-related peripheral nerve compression; early sign to reduce dose Uncommon (5-20%) Insulin resistance / elevated fasting glucose - real and dose-dependent; mean HbA1c rose 0.2 percentage points (95% CI 0.1 to 0.3) over 12 months in the 2-year trial; meaningful for pre-diabetics and diabetics Mild carpal tunnel symptoms - fluid-related; resolves on cessation; should prompt dose reduction Joint stiffness - IGF-1-mediated connective tissue effect; typically weeks 4-8; often resolves with continued dosing Mild elevation in liver enzymes (ALT/AST) - usually within normal limits; monitor but rarely clinically significant Rare but important Congestive heart failure signal - the CHF safety signal for MK-677 comes from the Adunsky 2011 hip-fracture Phase IIb trial (25 mg/day, N=123), which was terminated early after a small number of frail elderly patients developed CHF; it is attributed to fluid retention in vulnerable populations. The 2-year Nass trial in healthy older adults reported no CHF. This is the primary safety signal driving the "not in CHF, not in severe cardiac disease" contraindication Pituitary desensitization concerns - theoretical; not conclusively demonstrated in the 2-year trial but some users report reduced subjective response after 3-4 months of continuous dosing Elevated prolactin - rare at clinical doses but reported at higher doses; unique among "selective" GHS agents but dose-related Insulin resistance - the honest framing MK-677's effect on glucose metabolism is the most clinically important difference vs injectable GHS peptides. Mechanism: Direct GH-mediated hepatic glucose output increase Sustained ghrelin-receptor activation has independent glucose-intolerant effects Water retention complicates interpretation of labs In the 2-year trial, mean HbA1c rose 0.2 percentage points (95% CI 0.1 to 0.3) at 12 months on MK-677 25 mg/day and fell 0.1 on placebo (Nass et al., 2008). This is clinically small but not trivial: For healthy users: usually not clinically meaningful For pre-diabetics (fasting glucose 100-125 or HbA1c 5.7-6.4%): can push into overt T2DM territory For established T2DM: requires insulin/metformin adjustment and close monitoring What MK-677 does NOT do (or does less than) Does NOT significantly elevate cortisol (unlike GHRP-6 / hexarelin) Does NOT significantly elevate ACTH Does NOT cause injection-site reactions (it's oral) Does NOT cause the pulse-amplitude sleep disturbance some users get from injectable GHS Long-term uncertainty The Nass 2-year trial is the longest data we have. Beyond 2 years, safety is extrapolated: Chronic hyperinsulinism effects IGF-1-related cancer risk Pituitary somatotroph reserve Cardiovascular outcomes in the broader population (the Nass cohort was older adults, not the 25-45 year old biohacker demographic) Users should monitor: fasting glucose, HbA1c, IGF-1 (baseline and 4-6 weeks into dosing), PSA (men >40), and regular blood pressure. Cycling (8-16 weeks on / 4-8 weeks off) is the conservative approach although the mechanistic need for cycling is debated - unlike CJC-1295-DAC, MK-677 does not produce full somatotroph desensitization at clinical doses.

When to continue, reduce, or stop MK-677 (Ibutamoren)

MK-677 (Ibutamoren) contraindications

Absolute contraindications History of congestive heart failure (CHF) or any NYHA class II-IV cardiac dysfunction - the Adunsky 2011 hip-fracture Phase IIb trial (25 mg/day, N=123) was terminated early after a CHF safety signal in frail elderly patients; MK-677's water retention and sustained GH elevation can precipitate decompensation in vulnerable hearts Active malignancy - GH/IGF-1 axis may accelerate tumor growth. No direct MK-677 cancer data but inferred from general GH/IGF-1 literature ([Renehan et al., 2004]) Active diabetic retinopathy (proliferative or severe non-proliferative) - GH elevation can worsen retinopathy History of acromegaly or pituitary adenoma - superimposing sustained exogenous GH amplification on an already-hyperactive axis risks accelerating tumor growth and acromegalic progression Pregnancy or breastfeeding - no safety data; do not use Age <18 - pediatric GHD is managed with sermorelin or recombinant GH under endocrinology supervision, not MK-677 Relative contraindications (consult physician before use) Type 2 diabetes or pre-diabetes - MK-677 produces measurable glucose intolerance; use requires close monitoring and usually metformin co-therapy Uncontrolled hypertension - fluid retention can exacerbate blood pressure History of carpal tunnel syndrome - fluid retention and connective tissue expansion can worsen symptoms Hypothyroidism - optimize thyroid first Chronic kidney disease (CKD stage III+) - fluid retention can contribute to edema; dose reduction and close monitoring History of pituitary or hypothalamic surgery or radiation - altered somatotroph response; unpredictable Drug interactions Insulin and oral hypoglycemics - MK-677 impairs glucose tolerance; antidiabetic medication may need adjustment Corticosteroids (chronic systemic) - suppress GH axis and blunt MK-677 response CYP3A4 inhibitors/inducers - MK-677 is CYP3A4 metabolized; major inhibitors (ketoconazole, ritonavir) can elevate plasma levels; inducers (rifampin, carbamazepine) can reduce efficacy Exogenous GH (Somatropin) - do not combine Other GHS peptides or CJC-1295-DAC - do not combine (redundant, additive side effects) Specific drug combinations that require caution SSRI + MK-677 - no direct interaction but both can cause fluid retention; monitor NSAID chronic + MK-677 - both retain fluid; monitor edema Statins + MK-677 - no specific interaction; standard monitoring Monitoring requirements Baseline: IGF-1, fasting glucose, HbA1c, insulin, complete metabolic panel, thyroid panel, CBC, lipid panel, PSA (men >40), echocardiogram if any cardiac history Week 4-6: IGF-1, fasting glucose, insulin Week 8-12: Full panel + blood pressure + weight trend Every 12 weeks on long-term therapy: Full panel Annually: Full panel + consider imaging if symptomatic Discontinuation criteria Stop MK-677 and consult a clinician if you develop: Any chest pain, dyspnea, peripheral edema with weight gain >3 kg, orthopnea - possible CHF; urgent New or worsening carpal tunnel symptoms IGF-1 > 350 ng/mL (supraphysiologic in most adults) Fasting glucose consistently >115 mg/dL or HbA1c rising >0.4 points despite metformin Any new palpable mass, changing mole, unexplained weight loss (cancer workup) Severe headache, visual changes (rule out pituitary pathology) Unexplained fatigue, edema, or rapid weight gain (assess fluid balance, thyroid, glucose)

Why vendor quality drives MK-677 (Ibutamoren) side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

MK-677 (Ibutamoren) side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .